![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Adamas Levodopa-Induced Dyskinesia Candidate Reaches Primary Endpoint in Study
Adamas Levodopa-Induced Dyskinesia Candidate Reaches Primary Endpoint in Study
January 4, 2016
An Adamas Pharmaceuticals investigational compound to treat levodopa-induced dyskinesia associated with Parkinson’s disease demonstrated positive results in a Phase 3 study.
Patients receiving ADS-5102 (amantadine HCl) showed a 23 percent reduction in LID compared with placebo. This reduction was maintained at 24 weeks, according to Adamas.
Analyst Tim Lugo of William Blair says the results “clearly place Adamas ahead of private competitor Osmotica,” which also has a formulation of amantadine in Phase 3 development.
Upcoming Events
-
21Oct